235 related articles for article (PubMed ID: 33361398)
1. N-terminal pro-brain natriuretic peptide and sudden cardiac death in hypertrophic cardiomyopathy.
Wu G; Liu J; Wang S; Yu S; Zhang C; Wang D; Zhang M; Yang Y; Kang L; Zhao S; Hui R; Zou Y; Wang J; Song L
Heart; 2021 Oct; 107(19):1576-1583. PubMed ID: 33361398
[TBL] [Abstract][Full Text] [Related]
2. N-terminal pro-brain natriuretic peptide and adverse outcomes in Chinese patients with hypertrophic cardiomyopathy.
Zhang ZL; Xu YY; Qin Z; Lu YZ; Liu TD; Zhang L; Shangguan JH; Wang W; Tang JN; Zhang JY
Biosci Rep; 2022 Jan; 42(1):. PubMed ID: 34940836
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of N-terminal pro-brain natriuretic Peptide in outpatients with hypertrophic cardiomyopathy.
D'Amato R; Tomberli B; Castelli G; Spoladore R; Girolami F; Fornaro A; Caldini A; Torricelli F; Camici P; Gensini GF; Cecchi F; Olivotto I
Am J Cardiol; 2013 Oct; 112(8):1190-6. PubMed ID: 23871673
[TBL] [Abstract][Full Text] [Related]
4. Elevated Level of Troponin but Not N-Terminal Probrain Natriuretic Peptide Is Associated with Increased Risk of Sudden Cardiac Death in Hypertrophic Cardiomyopathy Calculated According to the ESC Guidelines 2014.
Rajtar-Salwa R; Hładij R; Dimitrow PP
Dis Markers; 2017; 2017():9417908. PubMed ID: 29358842
[TBL] [Abstract][Full Text] [Related]
5. Mid-regional proatrial natriuretic peptide for predicting prognosis in hypertrophic cardiomyopathy.
Bégué C; Mörner S; Brito D; Hengstenberg C; Cleland JGF; Arbustini E; Galve E; Wichter T; Richter A; Golmard JL; Bernard M; Dubourg O; Komajda M; Charron P; Isnard R
Heart; 2020 Feb; 106(3):196-202. PubMed ID: 31350276
[TBL] [Abstract][Full Text] [Related]
6. Relation between serum N-terminal pro-brain natriuretic peptide and prognosis in patients with hypertrophic cardiomyopathy.
Coats CJ; Gallagher MJ; Foley M; O'Mahony C; Critoph C; Gimeno J; Dawnay A; McKenna WJ; Elliott PM
Eur Heart J; 2013 Aug; 34(32):2529-37. PubMed ID: 23455360
[TBL] [Abstract][Full Text] [Related]
7. B-type natriuretic peptide and risk of sudden death in patients with hypertrophic cardiomyopathy.
Minami Y; Haruki S; Kanbayashi K; Maeda R; Itani R; Hagiwara N
Heart Rhythm; 2018 Oct; 15(10):1484-1490. PubMed ID: 29709578
[TBL] [Abstract][Full Text] [Related]
8. N-terminal pro-B-type natriuretic peptide is a specific predictor of appropriate device therapies in patients with primary prevention implantable cardioverter-defibrillators.
Sroubek J; Matos J; Locke A; Kaplinskiy V; Levine YC; Shen C; Buxton AE
Heart Rhythm; 2021 Jan; 18(1):71-78. PubMed ID: 32866691
[TBL] [Abstract][Full Text] [Related]
9. Degree and distribution of left ventricular hypertrophy as a determining factor for elevated natriuretic peptide levels in patients with hypertrophic cardiomyopathy: insights from cardiac magnetic resonance imaging.
Park JR; Choi JO; Han HJ; Chang SA; Park SJ; Lee SC; Choe YH; Park SW; Oh JK
Int J Cardiovasc Imaging; 2012 Apr; 28(4):763-72. PubMed ID: 21516440
[TBL] [Abstract][Full Text] [Related]
10. Higher copeptin levels are associated with worse outcome in patients with hypertrophic cardiomyopathy.
Sahin I; Gungor B; Ozkaynak B; Uzun F; Küçük SH; Avci II; Ozal E; Ayça B; Cetın S; Okuyan E; Dinckal MH
Clin Cardiol; 2017 Jan; 40(1):32-37. PubMed ID: 27768229
[TBL] [Abstract][Full Text] [Related]
11. [Value of N-terminal pro-B-type natriuretic peptide on long-term outcome of patients with hypertrophic cardiomyopathy].
Meng XB; Wang WY; Zhang K; Qi Y; An SM; Wang SY; Zheng JL; Yu QJ; Tang B; Wu R; Wang SY; Gao CY; Tang YD
Zhonghua Xin Xue Guan Bing Za Zhi; 2018 Mar; 46(3):192-197. PubMed ID: 29562423
[No Abstract] [Full Text] [Related]
12. N-terminal pro-B-type natriuretic peptide is associated with sudden cardiac death risk: the Cardiovascular Health Study.
Patton KK; Sotoodehnia N; DeFilippi C; Siscovick DS; Gottdiener JS; Kronmal RA
Heart Rhythm; 2011 Feb; 8(2):228-33. PubMed ID: 21044699
[TBL] [Abstract][Full Text] [Related]
13. Predictive Values of N-Terminal Pro-B-Type Natriuretic Peptide and Cardiac Troponin I for Myocardial Fibrosis in Hypertrophic Obstructive Cardiomyopathy.
Zhang C; Liu R; Yuan J; Cui J; Hu F; Yang W; Zhang Y; Chen Y; Qiao S
PLoS One; 2016; 11(1):e0146572. PubMed ID: 26765106
[TBL] [Abstract][Full Text] [Related]
14. Amino-terminal pro-B-type natriuretic peptide and high-sensitivity C-reactive protein as predictors of sudden cardiac death among women.
Korngold EC; Januzzi JL; Gantzer ML; Moorthy MV; Cook NR; Albert CM
Circulation; 2009 Jun; 119(22):2868-76. PubMed ID: 19470888
[TBL] [Abstract][Full Text] [Related]
15. The amount of late gadolinium enhancement outperforms current guideline-recommended criteria in the identification of patients with hypertrophic cardiomyopathy at risk of sudden cardiac death.
Freitas P; Ferreira AM; Arteaga-Fernández E; de Oliveira Antunes M; Mesquita J; Abecasis J; Marques H; Saraiva C; Matos DN; Rodrigues R; Cardim N; Mady C; Rochitte CE
J Cardiovasc Magn Reson; 2019 Aug; 21(1):50. PubMed ID: 31412875
[TBL] [Abstract][Full Text] [Related]
16. Usefulness of Serial N-terminal Pro-B-type Natriuretic Peptide Measurements to Predict Cardiac Death in Acute and Chronic Dilated Cardiomyopathy in Children.
den Boer SL; Rizopoulos D; du Marchie Sarvaas GJ; Backx AP; Ten Harkel AD; van Iperen GG; Rammeloo LA; Tanke RB; Boersma E; Helbing WA; Dalinghaus M
Am J Cardiol; 2016 Dec; 118(11):1723-1729. PubMed ID: 27692597
[TBL] [Abstract][Full Text] [Related]
17. The value of cardiac magnetic resonance and distribution of late gadolinium enhancement for risk stratification of sudden cardiac death in patients with hypertrophic cardiomyopathy.
Klopotowski M; Kukula K; Malek LA; Spiewak M; Polanska-Skrzypczyk M; Jamiolkowski J; Dabrowski M; Baranowski R; Klisiewicz A; Kusmierczyk M; Jasinska A; Jarmus E; Kruk M; Ruzyllo W; Witkowski A; Chojnowska L
J Cardiol; 2016 Jul; 68(1):49-56. PubMed ID: 26363820
[TBL] [Abstract][Full Text] [Related]
18. Predictors of Future Atrial Fibrillation Development in Patients with Hypertrophic Cardiomyopathy: A Prospective Follow-Up Study.
Tuluce K; Yakar Tuluce S; Kahya Eren N; Kocabas U; Akyildiz Akcay F; Gunduz R; Akyildiz ZI; Ergene O
Echocardiography; 2016 Mar; 33(3):379-85. PubMed ID: 26493159
[TBL] [Abstract][Full Text] [Related]
19. Relationships between P wave dispersion, atrial electromechanical delay, left atrial remodeling, and NT-proBNP levels, in patients with hypertrophic cardiomyopathy.
Tuluce K; Ozerkan F; Yakar Tuluce S; Yavuzgil O; Gurgun C; Bilgin M; Kahya Eren N; Kocabas U; Nalbantgil S; Soydas Cinar C
Cardiol J; 2015; 22(1):94-100. PubMed ID: 24671901
[TBL] [Abstract][Full Text] [Related]
20. Amount of left ventricular hypertrophy determines the plasma N-terminal pro-brain natriuretic peptide level in patients with hypertrophic cardiomyopathy and normal left ventricular ejection fraction.
Kim SW; Park SW; Lim SH; Kwon SU; Choi YJ; Park MK; Lee SC; Lee SH; Park JE; Jeon ES
Clin Cardiol; 2006 Apr; 29(4):155-60. PubMed ID: 16649724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
